海正药业(600267) - 2022 Q3 - 季度财报
HISUNHISUN(SH:600267)2022-10-27 16:00

Financial Performance - The company's operating revenue for Q3 2022 was CNY 3,007,219,050.77, a decrease of 3.09% compared to the same period last year[6] - The net profit attributable to shareholders for Q3 2022 was CNY 12,077,611.96, representing a significant decline of 94.49% year-on-year[6] - The basic earnings per share for Q3 2022 was CNY 0.010, down 94.71% year-on-year[10] - The diluted earnings per share for Q3 2022 was CNY 0.015, a decrease of 91.76% compared to the previous year[10] - The net profit for the third quarter of 2022 was CNY 338,165,183.70, a decrease of 39.3% compared to CNY 557,091,389.49 in the same period of 2021[41] - Operating profit for the third quarter was CNY 490,843,786.59, down from CNY 629,078,982.12 in the previous year, reflecting a decline of 21.9%[44] - Total profit for the quarter was CNY 487,612,975.20, compared to CNY 637,054,724.98 in the same quarter of 2021, marking a decrease of 23.4%[44] - The total comprehensive income for the quarter was CNY 350,857,033.41, down from CNY 552,048,779.79 in the same quarter of 2021, indicating a decline of 36.5%[42] Assets and Liabilities - The total assets at the end of Q3 2022 were CNY 18,538,503,941.99, a decrease of 4.31% from the end of the previous year[10] - Total liabilities were RMB 10,544,121,817.25, a decrease of 12.3% compared to RMB 12,028,750,319.54 in the previous year[36] - Current assets totaled RMB 6,129,953,019.17 as of September 30, 2022, a decrease of 3.7% from RMB 6,363,985,003.42 at the end of 2021[31] - Non-current assets amounted to RMB 12,408,550,922.82, down 4.6% from RMB 13,010,278,485.52 at the end of 2021[34] - Cash and cash equivalents were RMB 1,264,694,306.46, slightly down from RMB 1,295,750,258.65 at the end of 2021[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 65,813[19] - Zhejiang Haizheng Group Co., Ltd. holds 320,783,590 shares, accounting for 26.77% of total shares[19] - HPPC Holding SARL holds 79,111,673 shares, representing 6.60% of total shares[19] - Zhejiang International Trade Group Co., Ltd. holds 74,647,907 shares, which is 6.23% of total shares[19] - The company repurchased 24,305,959 shares, accounting for 2.03% of total share capital[22] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 1,477,548,911.76, an increase of 40.62% compared to the same period last year[10] - Cash flow from operating activities netted CNY 1,477,548,911.76, an increase of 40.5% compared to CNY 1,050,741,265.48 in the same period last year[45] - The net cash flow from investing activities was -$106.55 million, a decrease from -$317.77 million year-over-year[48] - Total cash inflow from financing activities was $4.25 billion, down from $6.89 billion compared to the previous period[48] - The net cash flow from financing activities was -$1.45 billion, compared to -$1.31 billion in the prior year[48] - Cash and cash equivalents at the end of the period totaled $1.10 billion, down from $1.43 billion year-over-year[48] Operational Efficiency - The company attributed the decline in net profit to a significant reduction in non-recurring gains compared to the previous year, while operational efficiency improvements contributed to the increase in core business profitability[16] - The company reported a net profit margin improvement, with net profit for the first three quarters showing signs of recovery compared to the previous year[36] - Research and development expenses increased to CNY 286,398,600.86 from CNY 264,445,837.71, reflecting a growth of 8.3%[44] - The company reported a decrease in sales expenses to CNY 1,721,334,091.93 from CNY 1,886,220,862.95, a reduction of 8.8%[44] Acquisitions and Transfers - The company agreed to transfer 90% of its subsidiary Zhejiang Ruijue Pharmaceutical Co., Ltd. for no less than an assessed value of 36.2968 million RMB[23] - The company completed the acquisition of its wholly-owned subsidiary Hangzhou Fuyang Spring City International Resort Co., Ltd. on September 9, 2022[26] - The company transferred 4.00% of its stake in Zhejiang Haizheng Animal Health Products Co., Ltd. for a total price of 100 million RMB[27] - The company’s shareholding in Zhejiang Haizheng Animal Health Products Co., Ltd. decreased from 70.343% to 66.343% after the transfer[27] Other Financial Metrics - Total operating revenue for the first three quarters of 2022 was RMB 8,743,908,274.30, a decrease of 4.0% compared to RMB 9,107,442,471.65 in the same period of 2021[36] - Total operating costs for the first three quarters of 2022 were RMB 8,165,087,259.06, down 5.4% from RMB 8,627,644,412.73 in the previous year[36] - Accounts receivable increased to RMB 2,347,976,727.26, up 12.2% from RMB 2,092,921,220.08 at the end of 2021[31] - Inventory decreased to RMB 1,635,984,158.74, down 19.1% from RMB 2,022,881,414.99 at the end of 2021[31] - Other comprehensive income after tax was CNY 12,691,849.71, compared to a loss of CNY 5,042,609.70 in the previous year[42] - The company’s financial statements for the third quarter of 2022 are not subject to audit opinions[28]